Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein

Journal of Nuclear Medicine

Volumn 39, Issue 1, 1998, Pages 77-86

  Crankshaw, Carolyn L ^b   Marmion, Mary ^b   Luker, Gary D ^b   Rao, Vallabhaneni ^b   Dahlheimer, Julie ^b   Burleigh, B Daniel ^b   Webb, Elizabeth ^b   Deutsch, Karen F ^b   Piwnica Worms, David ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Cyclosporin A; Metal complexes; Multidrug resistance; P glycoprotein; Technetium 99m

Indexed keywords

CYCLOSPORIN A; FURIFOSMIN TC 99M; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TETROFOSMIN TC 99M; UNCLASSIFIED DRUG; VALINOMYCIN; [2,2' (1,2 ETHANEDIYLDIIMINO)BIS(1,5 DIMETHOXY 5 METHYL 2 HEXEN 4 ONE)]BIS[METHYL BIS(3 METHOXYPROPYL)PHOSPHINE] TC 99M; [5,5' (1,2 ETHANEDIYLDIIMINO)BIS(2 ETHOXY 2 METHYL 4 PENTEN 3 ONE)]BIS[DIMETHYL(3 METHOXYPROPYL)PHOSPINE] TC 99M; [5,5' (1,2 ETHANEDIYLDIIMINO)BIS(2 ETHOXY 2 METHYL 4 PENTEN 3 ONE)]BIS[METHYL BIS(3 METHOXYPROPYL)PHOSPHINE] TC 99M;

ARTICLE; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL NOISE RATIO; SKIN CARCINOMA;

EID: 0031907855     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
2. Gros P, Ben Neriah Y, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986;323:728-731.
3. Shen DW, Fojo A, Chin JE, et al. Human multidrug-resistant cell lines: increased MDR1 expression can precede gene amplification. Science 1986;232:643-645.
4. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990:42:155-199.
5. Gaveriaux C, Boesch D, Jachez B. PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier. J Cell Pharmacol 1991;2:225-234.
6. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993;53:4595-4602.
7. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-1654.
8. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333: 1380-1385.
9. Morris M, Bordow S, Marshall G, Haber P, Cohn S, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996;334:231-238.
10. Wackers FJ, Berman D, Maddahi J, et al. Tc-99m-hexakis 2-methoxy isobutylisonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989;30:301-309.
11. Higley B, Smith FW, Smith T, et al. Technetium-99m-1,2-bis[bis(2-ethoxyethyl)phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993;34:30-38.
12. Rossetti C, Vanoli G, Paganelli G, et al. Human biodistribution, dosimetry and clinical use of technetium(III)-99m-Q12. J Nucl Med 1994;35:1571-1580.
13. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-984.
14. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 1994;35:510-515.
15. 99mTc-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995;16:253-257.
16. Crankshaw CL, Marmion M, Burleigh BD, Deutsch E, Piwnica-Worms D. Non-reducible mixed ligand Tc(III) cations (Q complexes) are recognized as transport substrates by the human multidrug-resistance (MDR) P-glycoprotein [Abstract]. J Nucl Med 1995;36:130P.
17. Piwnica-Worms D, Rao V, Kronauge J, Croop J, Characterization of multidrug-resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 1995;34:12210-12220.
18. Cordobes M, Starzec A, Delmon-Moingeon L, et al. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with MDR gene expression. J Nucl Med 1996;37:286-289.
19. Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG, Moore MJ. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996;37:1578-1582.
20. Del Vecchio S, Ciarmiello A, Potena MI, et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997;24:150-159.
21. Luker GD, Fracasso PM, Dobkin J, Piwnica-Worms D. Modulation of the multidrug resistance P-glycoprotein: detection with Tc-99m-sestamibi in vivo. J Nucl Med 1997;38:369-372.
22. Deutsch E, Vanderheyden J-L, Gerundini P, et al. Development of nonreducible technetium-99m(III) cations as myocardial perfusion imaging agents: initial experience in humans. J Nucl Med 1987;28:1870-1880.
23. Jurisson SS, Dancey K, McPartlin M, Tasker PA, Deutsch E. Synthesis, characterization, and electrochemical properties of technetium complexes containing both tetradentate Schiff base and monodentate tertiary phosphine ligands: single-crystal structure of trans-(N,N′-ethylenebis(acetylacetone iminato))bis(triphenylphosphine)technetium(III) hexafluorophosphate. Inorg Chem 1984;23:4743-4749.
24. 2OS and diamide dimercapto Schiff base ligands for use in radiopharmaceutical imaging agents [Abstract]. J Nucl Med 1991;32:1101.
25. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxy isobutyl isonitrile) technetium(I) in cultured chick myocardial cells: mitochondrial and plasma membrane potential dependence. Circulation 1990;82:1826-1838.
26. 2) ethylenediamine-bis[propyl(R-benzylimino)]metal(III) cations. J Med Chem 1996;39:3483-3490.
27. Piwnica-Worms D, Jacob R, Horres CR, Lieberman M. Transmembrane chloride flux in tissue-cultured chick heart cells. J Gen Physiol 1983;81:731-748.
28. -: carrier free? J Nucl Med 1975;16:639-641.
29. Glantz SA. Primer of biostatistics, 2nd ed. New York: McGraw-Hill, Inc.; 1987:379.
30. Choi K, Chen CJ, Kriegler M, Roninson IB. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the MDR1 (P-glycoprotein) gene. Cell 1988;53:519-529.
31. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med 1990;31:1646-1653.
32. Chernoff DM, Strichartz GR, Piwnica-Worms D. Membrane potential determination in large unilamellar vesicles with hexakis(2-methoxyisobutyl isonitrile) technetium(I). Biochim Biophys Acta 1993;1147:262-266.
33. Katzenellenbogen JA, Johnson HJJ, Myers HN. Photoaffinity labels for estrogen binding proteins of rat uterus. Biochemistry 1973;12:4085-4092.
34. Katzenellenbogen JA. The pharmacology of steroid radiopharmaceuticals: specific and non-specific binding and uptake selectivity. In: Nunn, A., ed. Radiopharmaceuticals: chemistry and pharmacology. New York: Marcel Dekker; 1992:297-331.
35. 2R′ is a monodentate tertiary phosphine ligand. Inorg Chem 1985;24:2134-2139.
36. Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC, Beck WT. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci USA 1989;86:5128-5132.
37. Herman LW, Sharma V. Kronauge JF, Barbaries E, Herman LA, Piwnica-Worms D. Novel hexakis(areneisonitrile)technetium(I) complexes as radioligands targeted to the multidrug resistance P-glycoprotein. J Med Chem 1995;38:2955-2963.
38. van Helvoort A, Smith AJ, Sprong H, et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996;87:507-517.